Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Xoma Corp (XOMA)

Xoma Corp (XOMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 291,091
  • Shares Outstanding, K 11,639
  • Annual Sales, $ 4,760 K
  • Annual Income, $ -40,830 K
  • 60-Month Beta 0.85
  • Price/Sales 58.71
  • Price/Cash Flow N/A
  • Price/Book 3.39
Trade XOMA with:

Options Overview Details

View History
  • Implied Volatility 79.70% ( +9.60%)
  • Historical Volatility 45.98%
  • IV Percentile 64%
  • IV Rank 52.95%
  • IV High 144.14% on 12/19/23
  • IV Low 7.19% on 02/16/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 2
  • Volume Avg (30-Day) 2
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 473
  • Open Int (30-Day) 453

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.26
  • Number of Estimates 3
  • High Estimate 0.00
  • Low Estimate -0.56
  • Prior Year -0.59
  • Growth Rate Est. (year over year) +55.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.29 +11.64%
on 06/10/24
26.54 -2.03%
on 06/13/24
+0.23 (+0.89%)
since 05/13/24
3-Month
23.00 +13.04%
on 03/27/24
27.00 -3.70%
on 04/03/24
+0.39 (+1.52%)
since 03/13/24
52-Week
13.48 +92.88%
on 10/04/23
27.00 -3.70%
on 04/03/24
+8.82 (+51.34%)
since 06/13/23

Most Recent Stories

More News
Xoma: Q1 Earnings Snapshot

Xoma: Q1 Earnings Snapshot

XOMA : 26.49 (+5.92%)
DocuSign, Gap rise; Costco, Marvell fall, Friday, 3/8/2024

Stocks that traded heavily or had substantial price changes on Friday: DocuSign, Gap rise; Costco, Marvell fall

XOMA : 26.49 (+5.92%)
GPS : 25.70 (-2.84%)
MDB : 220.50 (-3.82%)
COST : 842.37 (-0.64%)
DOCU : 51.00 (-0.62%)
Xoma: Q4 Earnings Snapshot

Xoma: Q4 Earnings Snapshot

XOMA : 26.49 (+5.92%)
Xoma: Q3 Earnings Snapshot

Xoma: Q3 Earnings Snapshot

XOMA : 26.49 (+5.92%)
Xoma: Q2 Earnings Snapshot

Xoma: Q2 Earnings Snapshot

XOMA : 26.49 (+5.92%)
Xoma: Q1 Earnings Snapshot

Xoma: Q1 Earnings Snapshot

XOMA : 26.49 (+5.92%)
Strength Seen in Vertex (VRTX): Can Its 5.0% Jump Turn into More Strength?

Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road....

VRTX : 479.78 (+0.84%)
XOMA : 26.49 (+5.92%)
Xoma: Q4 Earnings Snapshot

Xoma: Q4 Earnings Snapshot

XOMA : 26.49 (+5.92%)
Xoma (XOMA) Reports Q3 Loss, Misses Revenue Estimates

Xoma (XOMA) delivered earnings and revenue surprises of -140% and 95.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

XOMA : 26.49 (+5.92%)
TARS : 32.48 (-0.79%)
Xoma: Q3 Earnings Snapshot

Xoma: Q3 Earnings Snapshot

XOMA : 26.49 (+5.92%)

Business Summary

XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1' with potential...

See More

Key Turning Points

3rd Resistance Point 27.11
2nd Resistance Point 26.30
1st Resistance Point 25.65
Last Price 26.49
1st Support Level 24.19
2nd Support Level 23.38
3rd Support Level 22.73

See More

52-Week High 27.00
Last Price 26.49
Fibonacci 61.8% 21.84
Fibonacci 50% 20.24
Fibonacci 38.2% 18.64
52-Week Low 13.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar